Nothing Special   »   [go: up one dir, main page]

Zeiner et al., 2019 - Google Patents

Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients

Zeiner et al., 2019

View HTML
Document ID
2933031353234207236
Author
Zeiner P
Kinzig M
Divé I
Maurer G
Filipski K
Harter P
Senft C
Bähr O
Hattingen E
Steinbach J
Sörgel F
Voss M
Steidl E
Ronellenfitsch M
Publication year
Publication venue
Journal of Clinical Medicine

External Links

Snippet

(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references

Similar Documents

Publication Publication Date Title
Zeiner et al. Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients
Rosar et al. Efficacy and safety of [225Ac] Ac-PSMA-617 augmented [177Lu] Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis
Castello et al. Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors
Apostolidis et al. Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3)
Bumes et al. Non-invasive prediction of IDH mutation in patients with glioma WHO II/III/IV based on F-18-FET PET-guided in vivo 1H-magnetic resonance spectroscopy and machine learning
Khreish et al. Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy
Khreish et al. Value of combined PET imaging with [18F] FDG and [68Ga] Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu] Lu-PSMA-617 RLT
Kazerouni et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer
Laakmann et al. Radiological patterns of brain metastases in breast cancer patients: a subproject of the german brain metastases in breast cancer (BMBC) registry
Shen et al. Biphasic mathematical model of cell–drug interaction that separates target-specific and off-target inhibition and suggests potent targeted drug combinations for multi-driver colorectal cancer cells
Pijnappel et al. Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Lang et al. First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes
Galijasevic et al. Magnetic resonance spectroscopy in diagnosis and follow-up of gliomas: State-of-the-Art
Mahdal et al. New target for precision medicine treatment of giant-cell tumor of bone: sunitinib is effective in the treatment of neoplastic stromal cells with activated PDGFRβ signaling
Kim et al. Therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, based on diagnostic biomarker test in MET-addicted cancer
Würtemberger et al. Diffusion microstructure imaging to analyze perilesional T2 signal changes in brain metastases and glioblastomas
Saeki et al. Skeletal muscle volume is an independent predictor of survival after sorafenib treatment failure for hepatocellular carcinoma
Mazibuko et al. Subacute changes in N-acetylaspartate (NAA) following ischemic stroke: A serial MR spectroscopy pilot study
Boerrigter et al. RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Chiocchi et al. Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab
Chung et al. Radiation-induced metabolic shifts in the hepatic parenchyma: findings from 18F-FDG PET imaging and tissue NMR metabolomics in a mouse model for hepatocellular carcinoma
Gerritse et al. High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
Sirico et al. Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer
Lee et al. Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin
Miedema et al. 89Zr-Immuno-PET with immune checkpoint inhibitors: measuring target engagement in healthy organs